BALTIMORE, June 14, 2012 /PRNewswire/ -- Ameritox(SM), the nation's leader in pain medication monitoring, announced today that the Baltimore, MD, Federal Court issued a Preliminary Injunction order against Millennium Laboratories for misleading statements contained within a Millennium Laboratories press release. The Preliminary Injunction confirms the court's initial concerns about the Millennium Laboratories press release that led to its issuance of the Temporary Restraining Order on Wednesday, June 13, and moves from a temporary restriction to enjoining Millennium Laboratories' action regarding the press release. Following is the language directly from the Preliminary Injunction issued by the Court on Thursday, June 14, 2012:
"On June 13, 2012, Millennium and Ameritox entered into, and the Court approved, a Consent Order that concluded the above-captioned Lanham Act case. Docket No. 321. Later the same day, Millennium issued a press release (the "Press Release") concerning the litigation and the Consent Order. Docket No. 306-1. Upon motion by Ameritox, the Court granted a Temporary Restraining Order requiring, inter alia, that Millennium take down the Press Release from its web site, and enjoining Millennium's sales representatives from using the Press Release in sales presentations or communications. Docket No. 329.
On June 14, 2012, the Court reviewed written submissions from both sides and convened a sealed hearing. For reasons that the Court stated on the record, the undersigned granted Ameritox's motion to convert the Temporary Restraining Order to a Preliminary Injunction (Docket No. 324).1 This order effectuates that ruling.
To set the record straight, the Court will publish a brief opinion stating clearly the advertisements that were accused under the Lanham Act, the grounds upon which the advertisements were accused, the evidentiary limitations imposed by the Court, the recommendations of the advisory jury, and th
|SOURCE Ameritox Ltd.|
Copyright©2012 PR Newswire.
All rights reserved